Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches
Related Experiment Video
Updated: May 16, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Margarita Maurer1, Rajasekharan Somasundaram, Meenhard Herlyn
1Division of Immunology, Allergy and Infectious Diseases; Department of Dermatology; Vienna, Austria.
Abstract:
Several melanoma cell subpopulations with tumor-initiating and/or tumor-maintaining properties exist that may contribute to chemoresistance and tumor recurrence after standard therapies. One of these subpopulations expresses a B-cell marker, CD20. In a small pilot trial, we showed that a subset of Stage IV melanoma patients may potentially benefit from an adjuvant treatment using the anti-CD20 antibody rituximab.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

